Volume 91 Issue 24 | pp. 13-18
Issue Date: June 17, 2013

Cover Story

Pushing Cancer Over The Edge

After many disappointing studies, PARP inhibitors are finally showing promise as killers of cells already damaged by mutations
Department: Business
Keywords: oncology, pharmaceuticals, biotech, BRCA, ovarian cancer, breast cancer

A class of experimental drugs staged a quiet comeback last month at the American Society of Clinical Oncology’s annual meeting, held in Chicago. A cluster of studies suggested that compounds that block PARP, an enzyme involved in DNA repair, could be useful in treating ovarian and breast cancers driven by a mutation in BRCA, a gene that recently made headlines when actress Angelina Jolie revealed she carried the mutation.

The data presented at the ASCO . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society